Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
- Conditions
- Ovarian Cancer
- Interventions
- Registration Number
- NCT01706120
- Lead Sponsor
- National Cancer Institute, Naples
- Brief Summary
The addition of bevacizumab to first-line chemotherapy has been shown to improve progression free survival for patients with ovarian cancer. The purpose of this study is to explore the potential role of clinical and biologic factors in identifying those patients who benefit most from this combined therapy in terms of progression free and overall survival.
- Detailed Description
MITO-16 - MANGO-OV2 is a single-arm, open-label, non-comparative, multicenter, phase IV study. Patients will receive a combination of bevacizumab, paclitaxel and carboplatin as first line treatment (in-label dose and scheduling). This is an exploratory study attempting to identify potential prognostic clinical factors(such as hypertension) and prognostic biologic factors. Overall, 2 types of biomarkers are considered. Dynamic biomarkers are those expressing the changing nature of the disease in relation to the treatment or simply the tumour progression, these are typically not inherited. Genetic biomarkers are typically inherited and are expression of some characteristics potentially able to interfere with the treatment effect (i.e. Pharmacogenomics).
The safety of this regimen in routine clinical practice will also be described.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 400
- Female patients ≥18 years of age.
- Patients with histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma, including mixed Mullerian Tumours Or Recurrent early stage epithelial ovarian or fallopian tube carcinoma treated with surgery alone.
- FIGO stage IIIB & C or IV
- ECOG Performance Status of 0-2.
- Life expectancy of at least 12 weeks.
- Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.
- Availability of tumour samples for molecular analyses
Cancer related
-
Ovarian tumours with low malignant potential (i.e. borderline tumours)
-
Previous systemic anti-cancer therapy for advanced ovarian cancer.
-
History or evidence of brain metastases or spinal cord compression.
-
History or evidence of synchronous primary endometrial carcinoma, unless all of the following criteria related to the endometrial carcinoma are met:
- stage ≤Ia
- no more than superficial myometrial invasion
- no lymphovascular invasion
- not poorly differentiated (grade 3 or papillary serous or clear cell carcinoma).
-
Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
Other-treatment related
- Any prior radiotherapy to the pelvis or abdomen.
- Surgery (including open biopsy) within 4 weeks prior to the first bevacizumab dose or planned (In this case the patient can be enrolled but the administration of bevacizumab should be omitted at first cycle).
- Current or recent (within 10 days prior to the first study drug dose) use of full-dose oral or parenteral anticoagulant or thrombolytic agent for therapeutic purposes (except for central venous access patency, in which case international normalized ratio [INR] must be maintained below 1.5). Post operative prophylaxis with low molecular weight heparin sc is allowed.
- Current or recent (within 30 days of first study dosing) treatment with another investigational drug.
Laboratory related
-
Inadequate bone marrow function: ANC: <1.5 x 109/l, or platelet count <100 x 109/l or Haemoglobin <9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9 g/dl.
-
Inadequate coagulation parameters:
- activated partial thromboplastin time (APTT) >1.5 xULN or
- INR >1.5
-
Inadequate liver function, defined as:
- serum (total) bilirubin >1.5 x the upper limit of normal (ULN) for the institution
- AST/SGOT or ALT/SGPT >2.5 x ULN.
-
Inadequate renal function, defined as serum creatinine >2.0 mg/dl or >177 micromol/l
-
Proteinuria >1g in a 24-hour urine collection (to be performed only among patients who showed a ≥3+ at urine dipstick).
Patient related
-
Pregnant or lactating patients.
-
History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or sub-arachnoid haemorrhage within ≤6 months prior to the first study treatment).
-
Uncontrolled hypertension (sustained systolic >150 mm Hg and/or diastolic >100 mm Hg despite antihypertensive therapy) or clinically significant (i.e. active) cardiovascular disease, including:
- myocardial infarction or unstable angina within ≤6 months prior to the first study treatment
- New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)
- serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)
- peripheral vascular disease ≥grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision).
-
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the first study treatment.
-
Non-healing wound, ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require three weekly wound examinations.
-
Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description First-line chemotherapy with bevacizumab Bevacizumab * Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles * Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles * Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles First-line chemotherapy with bevacizumab Paclitaxel * Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles * Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles * Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles First-line chemotherapy with bevacizumab Carboplatin * Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles * Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles * Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
- Primary Outcome Measures
Name Time Method expression of soluble and tissutal biomarkers measured at baseline, at completion of chemotherapy, at disease progression or bevacizumab completion up to 15 monthsfor each patient
- Secondary Outcome Measures
Name Time Method overall survival three years number of patients taking oral antidiabetic therapy at baseline progression free survival one year number of patients taking antithrombotic therapy at baseline worst grade toxicity per patient evaluated every 3 weeks up to 15 month according to Common Toxicity Criteria for Adverse Events v. 4.03
Trial Locations
- Locations (47)
U.L.S.S. 13
🇮🇹Mirano, Italy
Ospedale Santa Croce
🇮🇹Fano, Italy
A.S.O. SS Antonio e Biagio e Cesare Arrigo
🇮🇹Alessandria, Italy
Ospedale Fatebenefratelli
🇮🇹Benevento, Italy
Centro di Riferimento Oncologico
🇮🇹Aviano, Italy
Spedali Civili - Università di Brescia
🇮🇹Brescia, Italy
Ospedale Senatore Antonio Perrino
🇮🇹Brindisi, Italy
Fondazione del Piemonte per l'Oncologia
🇮🇹Candiolo, Italy
Ospedale Ramazzini di Carpi /Ospedale di Mirandola
🇮🇹Carpi, Italy
Ospedale Cannizzaro
🇮🇹Catania, Italy
Azienda Ospedaliera Garibaldi Nesimadi Catania
🇮🇹Catania, Italy
Ospedale Mater Domini
🇮🇹Catanzaro, Italy
Ospedale Civile di Faenza
🇮🇹Faenza, Italy
A.O.U. Arcispedale Sant'Anna di Ferrara
🇮🇹Ferrara, Italy
E.O. Ospedali Galliera
🇮🇹Genova, Italy
IRCCS San Martino IST
🇮🇹Genova, Italy
Ospedale Fabrizio Spaziani di Frosinone / Osp. SS Trinità di Sora
🇮🇹Frosinone, Italy
Ospedale A. Manzoni
🇮🇹Lecco, Italy
Ospedale di Guastalla
🇮🇹Guastalla, Italy
Ospedale Mater Salutis
🇮🇹Legnago, Italy
A.O. C. Poma
🇮🇹Mantova, Italy
Presidio Ospedaliero Manerbio
🇮🇹Manerbio, Italy
Istituto Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Istituto Nazionale Tumori
🇮🇹MIlano, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
Ospedale S. Gerardo
🇮🇹Monza, Italy
A.O.U. Policlinico Modena
🇮🇹Modena, Italy
AOU Policlinico Federico II
🇮🇹Napoli, Italy
Istituto Oncologico Veneto
🇮🇹Padova, Italy
Istituto Nazionale dei Tumori
🇮🇹Napoli, Italy
Istituto Sacro Cuore Don Calabria
🇮🇹Negrar, Italy
Ospedale Santa Chiara
🇮🇹Pisa, Italy
Fondazione IRCCS S. Matteo
🇮🇹Pavia, Italy
Ospedale Silvestrini
🇮🇹Perugia, Italy
A.O. Santa Maria degli Angeli
🇮🇹Pordenone, Italy
Ospedale S. Maria delle Croci
🇮🇹Ravenna, Italy
Arcispedale S. Maria Nuova
🇮🇹Reggio Emilia, Italy
Ospedale degli Infermi / Ospedale Civile
🇮🇹Rimini, Italy
Ospedale S. Giovanni Calibita Fatebenefratelli
🇮🇹Roma, Italy
Istituto Regina Elena
🇮🇹Roma, Italy
Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore
🇮🇹Roma, Italy
ASS N 1 Triestina
🇮🇹Trieste, Italy
A.O. Ordine Mauriziano
🇮🇹Torino, Italy
A.O.U. OIRM-S. Anna
🇮🇹Torino, Italy
A.O. di Udine S. Maria delle Misericordia
🇮🇹Udine, Italy
Ospedale del Ponte
🇮🇹Varese, Italy